Skip to content

Resonance Breathing Training for Long Covid-related Myocardial Injury

An Investigation of the Efficacy of Resonance Breathing Training in the Rehabilitation of Patients with Long Covid-related Myocardial Injury

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06379672
Enrollment
70
Registered
2024-04-23
Start date
2024-08-25
Completion date
2024-10-05
Last updated
2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long COVID, Myocardial Injury

Keywords

2D-STE, resonance breathing, Myocardial Injury, Long Covid-19

Brief summary

An investigation of the efficacy of resonance breathing training in the rehabilitation of patients with Long covid-related myocardial injury

Interventions

Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.

Sponsors

Chengdu Sport University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Age between 18 and 60 years; 2. According to the WHO definition: one or more systemic involvement present 3 months after the diagnosis of a new crown infection, and at least 2 of these months cannot be explained by other diseases 3. 2D-STE suggestive of GLSAVG: -17% ≤ men ≤ -10%, -18% ≤ women ≤ -10%; 4. Consent for enrollment based on the degree of myocardial injury, as diagnosed by a clinician; 5. Signing the informed consent form with the consent of the patient or his/her family members

Exclusion criteria

* (1) Previous history of coronary atherosclerotic heart disease and heart failure; (2) Combination of severe arrhythmia or cardiogenic shock; (3) Combination of severe hypertension, hypertrophic cardiomyopathy, valvular disease of moderate or higher grade, acute myocarditis or pericarditis; (4) Combination of any disease that severely affects limb movement, such as musculoskeletal system disease or severe hepatic or renal insufficiency; (5) Combination of progressive malignant tumors, infectious diseases, bleeding disorders, autoimmune diseases, etc; Those who have serious mental illness and are unable to cooperate

Design outcomes

Primary

MeasureTime frameDescription
New YorkHeart Association (NYHA)12weeksThe scale is divided into four levels Grade 1 is unrestricted activity. Daily physical activity does not cause significant shortness of breath, fatigue or palpitations Grade 2 is a mild limitation of activity. Asymptomatic at rest, daily activities may cause significant shortness of breath, fatigue or palpitations Grade 3 is marked limitation of activity. May be asymptomatic at rest, but may cause significant shortness of breath, fatigue, or palpitations with less than daily activity. Grade 4 is symptomatic at rest, with discomfort associated with any physical activity. Class IVa for those who can move around indoors or at the bedside without intravenous drug administration; Class IVb for those who cannot get out of bed and require intravenous drug administration.
left ventricle global longitudinal strain, LVGLS12weeksThe magnitude of overall longitudinal myocardial strain in the left ventricle on two-dimensional speckle tracking echocardiograms as an average of the peak longitudinal strain in all myocardial segments. The normal range is (-25% to -17%) in men and (-25% to -18%) in women.

Secondary

MeasureTime frameDescription
hypertension12weeksBlood pressure included both systolic and diastolic blood pressure and was observed before and after the intervention for any reduction in blood pressure.
Average heart rate12weeksOne-minute average heart rate (at rest).

Contacts

Primary ContactRui Li
wp100331@cdsu.edu.cn17711524016
Backup ContactRui Li
17711524016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026